Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,231.10 | 2.60 | 0.03% |
| CAC 40 | 7,717.44 | 7.63 | 0.10% |
| DAX 40 | 24,052.86 | 100.01 | -0.41% |
| Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
| FTSE 100 | 9,275.99 | 10.19 | 0.11% |
| HKSE | 25,201.76 | 323.16 | -1.27% |
| NASDAQ | 21,544.27 | 94.98 | 0.44% |
| Nikkei 225 | 42,520.27 | 125.87 | 0.30% |
| NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
| S&P 500 | 6,465.94 | 26.62 | 0.41% |
| S&P/ASX 200 | 8,960.50 | 0.70 | -0.01% |
| SSE Composite Index | 3,800.35 | 68.03 | -1.76% |